Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...
Another reason for nobody stepping up to write new man-pages was that the standardized format is Groff, which is now 35 years ...
Also: Linux will be unstoppable in 2026 - but one open-source legend may not survive One way to do this is via Distrobox.
Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.